This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Meta-Analysis

. 1991:138:167-77.

Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group

Affiliations

PMID: 1838428

Meta-Analysis

Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group

C Bouffioux. Scand J Urol Nephrol Suppl. 1991.

. 1991:138:167-77.

Author

Affiliation

¹ Department of Urology, University Hospital Liège, Belgium.

PMID: 1838428

No abstract available

PubMed Disclaimer

Similar articles

Intravesical therapy for superficial bladder cancer.
Malkowicz SB. Malkowicz SB. Semin Urol Oncol. 2000 Nov;18(4):280-8. Semin Urol Oncol. 2000. PMID: 11101091 Review.
Management of superficial transitional cell carcinoma of the bladder.
Fleischmann J, Goldberg G. Fleischmann J, et al. Semin Urol. 1993 Nov;11(4):193-204. Semin Urol. 1993. PMID: 8290825 Review.
Superficial bladder disease: case studies and therapeutic advances.
Soloway MS, Droller MJ, Flanigan RC, Nseyo UO. Soloway MS, et al. Urology. 1992 Dec;40(6 Suppl):11-22. Urology. 1992. PMID: 1466118 No abstract available.
[Treatment and follow-up of superficial bladder cancer].
Raitanen M. Raitanen M. Duodecim. 2002;118(9):903-9. Duodecim. 2002. PMID: 12238168 Review. Finnish. No abstract available.
BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne FM, van der Meijden AP, Franssen MP. Debruyne FM, et al. Prog Clin Biol Res. 1989;303:435-46. Prog Clin Biol Res. 1989. PMID: 2506556 Clinical Trial. No abstract available.

See all similar articles

Cited by

Evolving immunotherapeutic strategies in bladder and renal cancer.
Griffiths TR, Mellon JK. Griffiths TR, et al. Postgrad Med J. 2004 Jun;80(944):320-7. doi: 10.1136/pgmj.2003.013508. Postgrad Med J. 2004. PMID: 15192163 Free PMC article. Review.
Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy.
Hall RR, Parmar MK, Richards AB, Smith PH. Hall RR, et al. BMJ. 1994 Jan 22;308(6923):257-60. doi: 10.1136/bmj.308.6923.257. BMJ. 1994. PMID: 8179678 Free PMC article.
Bladder cancer.
Leung HY, Griffiths TR, Neal DE. Leung HY, et al. Postgrad Med J. 1996 Dec;72(854):719-24. doi: 10.1136/pgmj.72.854.719. Postgrad Med J. 1996. PMID: 9015464 Free PMC article. Review.
BCG in the treatment of superficial cancer of the bladder: a review.
Friberg S. Friberg S. Med Oncol Tumor Pharmacother. 1993;10(1-2):31-6. doi: 10.1007/BF02987766. Med Oncol Tumor Pharmacother. 1993. PMID: 8258992 Review.
Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
Serretta V, Corselli G, Piazza B, Lio D, Gervasi F, Salerno S, Pavone-Macaluso M. Serretta V, et al. Urol Res. 1993;21(5):353-7. doi: 10.1007/BF00296836. Urol Res. 1993. PMID: 8279093 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information